Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
In stock of library
DOI
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
In situ metabolomics in cancer by mass spectrometry imaging.
Adv. Cancer Res. 134, 117-132 (2017)
Metabolomics is a rapidly evolving and a promising research field with the expectation to improve diagnosis, therapeutic treatment prediction, and prognosis of particular diseases. Among all techniques used to assess the metabolome in biological systems, mass spectrometry imaging is the method of choice to qualitatively and quantitatively analyze metabolite distribution in tissues with a high spatial resolution, thus providing molecular data in relation to cancer histopathology. The technique is ideally suited to study tissues molecular content and is able to provide molecular biomarkers or specific mass signatures which can be used in classification or the prognostic evaluation of tumors. Recently, it was shown that FFPE tissue samples are also suitable for metabolic analyses. This progress in methodology allows access to a highly valuable resource of tissues believed to widen and strengthen metabolic discovery-driven studies.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Diagnostic ; Ffpe Tissue ; Maldi ; Mass Spectrometry Imaging ; Metabolomics ; Predictive ; Prognostic Pathology; Predictive Molecular Pathology; Intratumor Heterogeneity; Breast-cancer; Biomarker Discovery; Clinical-relevance; Tissue-sections; Gastric-cancer; Diagnosis; Tumors; Cells
ISSN (print) / ISBN
0065-230x
Journal
Advances in Cancer Research
Quellenangaben
Volume: 134,
Pages: 117-132
Publisher
Elsevier
Publishing Place
San Diego
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Research Unit Analytical Pathology (AAP)